Bio-Rad(US:BIO)2026-02-13 02:50Financial Performance - Bio-Rad's Life Science segment generated approximately 40% of consolidated net sales, while the Clinical Diagnostics segment accounted for 60% for the year ended December 31, 2025[9]. - The estimated worldwide sales for Life Science products are approximately $19 billion, with principal customers including universities, government agencies, and pharmaceutical manufacturers[10]. - The Clinical Diagnostics segment's estimated worldwide sales are approximately $16 billion, supporting over 300 clinical diagnostic tests[12]. Workforce and Operations - Bio-Rad employs approximately 770 sales personnel globally, enhancing customer engagement and long-term relationships[18]. - The company had approximately 790 employees focused on research and development as of December 31, 2025, indicating a strong commitment to innovation[25]. - Bio-Rad operates in over 36 countries, with approximately 40% of sales generated from the U.S. and 60% from international markets, primarily Europe[8][9]. - Bio-Rad's workforce consists of approximately 7,450 employees, with 46% located in the Americas, 36% in Europe, and 18% in Asia Pacific[35]. Intellectual Property - The company holds over 2,100 U.S. and international patents, emphasizing its focus on intellectual property as a valuable asset[16]. Regulatory Compliance - The company is subject to various regulatory requirements, including compliance with FDA regulations for its diagnostic products[26][30]. Revenue Model - Bio-Rad's clinical diagnostics portfolio generates recurring revenue through ongoing sales of test kits and consumables, indicating a stable revenue model[13]. Investment and Financial Position - As of December 31, 2025, the fair value of the company's investment in Sartorius was $5,669.2 million, representing approximately 38% of the outstanding ordinary shares and 28% of the preference shares[40]. - Sartorius reported sales revenue of €3,380.7 million and a net profit of €137.4 million for the year ended December 31, 2024[42]. - The company's cash flow from operating activities for Sartorius was €976.2 million, while cash flow from investing activities was negative at €(425.8) million[42]. - The company had $1.20 billion in principal amount of fixed-rate long-term debt outstanding as of December 31, 2025[176]. - Sartorius's total current assets were €2,113.7 million and total non-current assets were €7,989.3 million as of December 31, 2024[42]. - The company's equity as of December 31, 2024, was reported at €3,897.8 million[42]. Foreign Currency and Interest Rate Risks - A hypothetical 10% depreciation/appreciation of foreign currencies relative to the U.S. dollar would result in an unrealized gain/loss of $59.9 million on the company's derivative position as of December 31, 2025[174]. - A 10% depreciation/appreciation on the quoted stock prices for Sartorius shares at December 31, 2025, would result in an approximate loss/gain of $566.9 million reported in the financial statements[177]. - The company centrally manages foreign currency exposures and uses forward contracts to hedge against foreign exchange risks[172]. - Interest rate changes could impact the fair value of the company's fixed-income investment portfolio, with a hypothetical increase or decrease in interest rates by 50 and 100 basis points resulting in a change of approximately $9.9 million and $20.0 million, respectively[175].